Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.
There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.
Cancer Immunobiology Center, University of Texas Southwestern Medical School, Dallas, USA. ellen.vitetta@utsouthwestern.edu
Ellen S
ES
Vitetta
Joan E
JE
Smallshaw
John
J
Schindler
D000327:Adsorption; D000328:Adult; D000536:Aluminum Hydroxide; D000906:Antibodies / Q000276:immunology; D000917:Antibody Formation; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012276:Ricin / Q000037:antagonists & inhibitors / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
D000906:Antibodies; C509236:RiVax; D014612:Vaccines; D014614:Vaccines, Synthetic; D000536:Aluminum Hydroxide; D012276:Ricin